Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Screening per il cancro ovarico nelle pazienti anziane (PLCO Screening Trial)

10 novembre 2026 aggiornato da: National Cancer Institute (NCI)

Prova di screening del cancro alla prostata, ai polmoni, al colon-retto e alle ovaie (PLCO).

This clinical trial studies whether screening methods used to diagnose cancer of the prostate, lung, colon, rectum, or ovaries can reduce deaths from these cancers. Screening tests may help doctors find cancer cells early and plan better treatment for ovarian cancer. The ovarian cancer screening tests are part of a trial that addresses the screening of four cancer sites, each with their own results record: prostate (NCT00002540), lung (NCT01696968), colorectal (NCT01696981), and ovarian (NCT01696994).

Panoramica dello studio

Stato

Attivo, non reclutante

Condizioni

Intervento / Trattamento

Descrizione dettagliata

PRIMARY OBJECTIVES:

I. To determine whether screening with CA125 and transvaginal ultrasound (TVU) can reduce mortality from ovarian cancer in women aged 55-74 at entry.

SECONDARY OBJECTIVES:

I. To assess screening variables, other than mortality, for each of the interventions including sensitivity, specificity, and positive predictive value.

II. To assess the incidence, stage, and survival of cancer cases. III. To investigate the mortality predictive value of biologic and/or prognostic characterizations of tumor tissue as intermediate endpoints.

IV. To conduct biomolecular and genetic research into factors associated with cancer carcinogenesis and promotion, as well as the early detection of these factors.

OUTLINE: Participants in the overall PLCO study are stratified by screening center, gender, and age (55-59 vs 60-64 vs 65-69 vs 70-74). Participants are randomized to 1 of 2 arms (control vs screening).

ARM I (Control): Participants receive standard medical care. Participants complete a Diet History Questionnaire (DHQ) at baseline.

ARM II (Ovarian Screening): Participants undergo blood sample collection for CA125 analysis at baseline annually for 5 years. Serum that is not used in the study will be stored in an NCI biorepository. Participants also undergo an ovarian palpation exam (OVR, discontinued in December 1998) and TVU at baseline and annually for 3 years. A scheduling and tracking procedure is implemented to ensure regular attendance at repeat screens for participants screened negative or for those who are designated suspicious or positive at screening but for whom subsequent diagnostic procedures do not reveal ovarian cancer (follow-up diagnostic procedures are through their own medical care environment). Participants diagnosed with ovarian cancer via a screening test are referred for treatment in accordance with current accepted practice for appropriate stage of disease, patient age, and medical condition; a procedure is provided for contact with qualified medical personnel to insure appropriate therapy.

Participants complete a Dietary Questionnaire (DQX) at baseline and DHQ at year 3. An Annual Study Update (ADU) (previously referred to as the Periodic Survey of Health [PSH] questionnaire) is mailed to each participant annually for 13 years to identify all prevalent and incident cancers of the ovaries as all deaths that occur among both screened and control subjects during the trial.

After completion of screening, participants are followed up for at least 13 years.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

78216

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Maryland
      • Bethesda, Maryland, Stati Uniti, 20892
        • National Institutes of Health Clinical Center

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 55 anni a 74 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Femmina

Descrizione

Exclusion Criteria:

  • Women who at the time of randomization are less than 55 or greater than or equal to 75 years of age

  • Individuals undergoing treatment for cancer at this time, excluding basal-cell and squamous-cell skin cancer

  • Individuals with known prior cancer of the colon, rectum, lung, or ovary

    • This includes primary or metastatic PLCO cancers
  • Individuals with previous surgical removal of the entire colon or one lung

    • Until October 1996, women with previous surgical removal of both ovaries were excluded from the trial. In order to increase the enrollment of women into the trial, beginning in October 1996, these women were no longer excluded for this reason.
  • Individuals who are participating in another cancer screening or cancer primary prevention trial

  • Prior to April 1, 1999 women were excluded from the trial if they were currently taking or had taken Tamoxifen or Evista\Raloxifene in the past 6 months. As of April 1999 based on a decision from the PLCO Ovary Subcommittee, women who have or are currently taking Tamoxifen or Evista\Raloxifene are not excluded from participation.

  • Individuals who are unwilling or unable to sign the informed consent form

  • Individuals who have had a colonoscopy, sigmoidoscopy, or barium enema in the past three years

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Selezione
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Separare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Nessun intervento: Control

Participants receive standard medical care. Participants complete a DHQ at baseline.

Comparatore attivo: Ovarian Screening

Participants undergo blood sample collection for CA125 analysis at baseline annually for 5 years. Serum that is not used in the study will be stored in an NCI biorepository. Participants also undergo an OVR (discontinued in December 1998) and TVU at baseline and annually for 3 years. Participants complete a DQX at baseline and DHQ at year 3. An ADU (previously referred to as the PSH questionnaire) is mailed to each participant annually for 13 years to identify all prevalent and incident cancers of the ovaries as all deaths that occur among both screened and control subjects during the trial.

Correlative studies

Undergo questionnaire assessments

Undergo TVU

Altri nomi:
  • Ultrasuoni
  • Imaging a ultrasuoni bidimensionale in scala di grigi
  • Ecografia bidimensionale
  • 2D-USA
  • Prova ad ultrasuoni
  • Ecografia, medica
  • NOI
  • Ecografia

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Ovarian Cancer Deaths (Including Primary Peritoneal and Fallopian Tube Cancers)
Lasso di tempo: Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.

Ovarian cancer deaths confirmed in participants by a death review committee if available, otherwise by death certificate.

Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
Ovarian Cancer Death Rates (Including Primary Peritoneal and Fallopian Tube Cancers)
Lasso di tempo: Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.

Ovarian cancer deaths confirmed in participants by a death review committee if available, otherwise by death certificate. Rate is the number of deaths divided by person years of follow-up in the study.

Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Deaths From All Causes
Lasso di tempo: Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.

Deaths from all causes were compared between the ovarian cancer screening arm and the usual care arm.

Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
Death Rates From All Causes
Lasso di tempo: Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.

Deaths from all causes were compared between the ovarian cancer screening arm and the usual care arm. Rate is the number of deaths divided by person years of follow-up in the study.

Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
Ovarian Cancer Incidence (Including Primary Peritoneal and Fallopian Tube Cancers)
Lasso di tempo: Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.

Ovarian cancer diagnoses confirmed by medical record abstraction.

Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
Ovarian Cancer Incidence Rates (Including Primary Peritoneal and Fallopian Tube Cancers).
Lasso di tempo: Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.

Ovarian cancer diagnoses confirmed by medical record abstraction. Incidence rate (cumulative) defined as ovarian cancer diagnoses divided by person years at risk for ovarian cancer.

Events through 13 years of follow-up or through December 31, 2009; median follow-up 11.9 years.
Complications of Diagnostic Evaluation (DE) Following a Positive Screening Test
Lasso di tempo: One year from screening examination

Number of positive screens with complications

One year from screening examination
T0 (Baseline) CA-125 Screening Results
Lasso di tempo: T0 (at study entry)

Cancer Antigen 125 (CA-125) result.

T0 (at study entry)
T0 (Baseline) TVU Screening Results
Lasso di tempo: T0 (at study entry)

Transvaginal Ultrasound (TVU) result.

T0 (at study entry)
T1 CA-125 Screening Results
Lasso di tempo: T1 (one year after entry)

Cancer Antigen 125 (CA-125) result.

T1 (one year after entry)
T1 TVU Screening Results
Lasso di tempo: T1 (one year after entry)

Transvaginal Ultrasound (TVU) result.

T1 (one year after entry)
T2 CA-125 Screening Results
Lasso di tempo: T2 (two years after entry)

Cancer Antigen 125 (CA-125) result.

T2 (two years after entry)
T2 TVU Screening Results
Lasso di tempo: T2 (one year after entry)

Transvaginal Ultrasound (TVU) result.

T2 (one year after entry)
T3 CA-125 Screening Results
Lasso di tempo: T3 (three years after entry)

Cancer Antigen 125 (CA-125) result.

T3 (three years after entry)
T3 TVU Screening Results
Lasso di tempo: T3 (three years after entry)

Transvaginal Ultrasound (TVU) result.

T3 (three years after entry)
T4 CA-125 Screening Results
Lasso di tempo: T4 (four years after entry)

Cancer Antigen 125 (CA-125) result.

T4 (four years after entry)
T5 CA-125 Screening Results
Lasso di tempo: T5 (five years after entry)

Cancer Antigen 125 (CA-125) result.

T5 (five years after entry)

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Investigatore principale: Christine D Berg, National Cancer Institute (NCI)

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

16 novembre 1993

Completamento primario (Effettivo)

21 maggio 2012

Completamento dello studio (Stimato)

30 giugno 2027

Date di iscrizione allo studio

Primo inviato

28 settembre 2012

Primo inviato che soddisfa i criteri di controllo qualità

1 ottobre 2012

Primo Inserito (Stimato)

2 ottobre 2012

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

13 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

10 novembre 2026

Ultimo verificato

1 luglio 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • NCI-2012-01758
  • CDR0000078532
  • NCI-P93-0050
  • PLCO-1
  • NCI-2012-01758 (Identificatore di registro: CTRP (Clinical Trial Reporting Program))
  • PLCO-Ovarian (Altro identificatore: National Cancer Institute)

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .